Navigation Links
Novalung Records 50% Growth
Date:3/23/2010

ANN ARBOR, Mich., March 23 /PRNewswire/ -- The innovative therapies for lung failure from medical device company Novalung GmbH continue to gain acceptance.  Additional financing will allow the Talheim (Germany) based company to accelerate the development of new products.

Novalung GmbH increased sales by 50% in 2009.  The increasing acceptance of the company's innovative therapies for lung failure both in Germany and abroad is driving continuing growth. Manufacturing operations moved into a new, larger clean-room facility at the end of 2009.

In order to maintain this growth and to fund further international expansion, the private equity group Zukunftsfonds Heilbronn GmbH & Co.KG ("Future Fund of Heilbronn", zfhn) and the LBank, state bank of Baden-Wurttemberg, completed an additional financing round for Novalung. The zfhn acted as lead investor for the second time.

Thanks to the additional funding, commercialization of new products can be pursued more aggressively. These measures put Novalung in an excellent position to establish itself internationally as the pioneering provider of solutions for lung failure, and to revolutionize the treatment of lung failure with new therapies.

Novalung products allow a paradigm shift from the mechanically ventilated patient in an artificial coma to the awake, mobile patient breathing spontaneously. The innovative technologies to replace mechanical ventilation and eliminate the associated ventilator-induced lung injury advance this approach and provide physicians, nurses and patients with new therapeutic options.

Novalung's vision for the future for the long-term treatment of patients with advanced lung disease is a small, wearable artificial lung that frees patients from respiratory stress, improves their overall condition and thus improves their quality of life.

Founded in 2003, Novalung GmbH operates on a highly international level in order to establish new solutions for lung failure. These advanced technologies from Germany and the U.S. were brought into the company and developed further.  Novalung's devices have been used to treat more than 5,000 patients.

The privately funded Novalung GmbH is a fast growing medical technology company based in the area of Heilbronn, Germany, with a subsidiary in Ann Arbor, Michigan.

Novalung has received limited FDA clearance to market its devices in the U.S., and the company plans to begin clinical trials here in 2010 to expand its indications in extracorporeal lung support.

SOURCE Novalung, Inc.

Back to top

RELATED LINKS
http://www.novalung.com

'/>"/>

SOURCE Novalung, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Praxis Electronic Medical Records Announces New Version 5 With Breakthrough in EHR Documentation
2. Aprima and MednetwoRx Partner to Provide Electronic Health Records and Remote Hosting Option to Physician Practices
3. Vicus Therapeutics Records Last Patient Visit of Phase 2, VT-122 Trial for the Treatment of Cachexia in Patients With Advanced Lung Cancer
4. Kensey Nash To Participate in the Sidoti Fourteenth Annual New York Emerging Growth Institutional Investor Forum
5. NOVAVAX to Present at 22nd Annual ROTH OC Growth Stock Conference
6. Vermillion to Present at the Roth 22nd Annual OC Growth Stock Conference March 15 - 17, Laguna Niguel, CA
7. Keryx Biopharmaceuticals to Present at the 22nd Annual ROTH OC Growth Stock Conference
8. Anadys Pharmaceuticals to Present at the ROTH OC Growth Stock Conference
9. International Growth Continues: Rhythmlink International, LLC Receives CE Marking & ISO 13485 Certification
10. DUSA Pharmaceuticals to Present at Roth Capital Partners 22nd Annual OC Growth Stock Conference
11. Acuo Technologies Announces Another Significant Sales and Implementation Growth Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... and PITTSBURGH, Feb. 10, 2016 Mylan N.V. (NASDAQ, ... quarter and year ended December 31, 2015. ... Full year adjusted total revenues of $9.45 billion, up ... year; GAAP total revenues of $9.43 billion. Excluding the ... markets specialty and branded generics business (the "EPD Business"), ...
(Date:2/10/2016)... , Feb. 10, 2016  Resolve Therapeutics, ... transformative new approaches to the treatment of lupus ... of a multiple ascending dose study in patients ... compound RSLV-132. --> ... placebo-controlled multiple ascending dose study of RSLV-132 in ...
(Date:2/10/2016)... , Feb. 10, 2016  Rich Pharmaceuticals, Inc. (OTC ... a 1-for-100 reverse split of its issued and outstanding ... trading on Thursday, February 11, 2016. The Company,s common ... CUSIP number 76303T308 and temporary ticker symbol "RCHAD". After ... under the ticker symbol (RCHA).  --> ...
Breaking Medicine Technology:
(Date:2/10/2016)... ... February 10, 2016 , ... LaserShip, a regional parcel carrier that services the ... Eastern Michigan last Friday in order to aid in the Flint water crisis. In ... a facility located in Clio, only 15 miles away from Flint. , “We have ...
(Date:2/10/2016)... ... February 10, 2016 , ... InDemand ... within Healthcare, recently partnered with Heart City Health Center to improve ... 23 years, Heart City Health Center has provided the Elkhart community with access ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... 10 ... Brand. There were three leading bottled water brand owners that topped the list as ... enhance connectivity and optimize conversion. The premier brand was Tibet 5100, a top notch ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... welcomes S.S. Nesbitt as the latest addition to its growing list of Partner ... locations throughout the Southeast, from Orlando to Huntsville and in between. , Harnessing ...
(Date:2/10/2016)... ... February 10, 2016 , ... Pediatric therapists are challenged to ... shows that the Goal Attainment Scale (GAS) captures 20% more change in outcomes ... more about the Goal Attainment Scale, Education Resources Inc. is offering a course ...
Breaking Medicine News(10 mins):